This Phase 3 study is designed to evaluate the efficacy and safety of IN-B00009 injection in adults with obesity or overweight without diabetes mellitus
Aged 19 to 75 years as of the date of written consent
Those who meet any of the following obesity criteria at the screening visit
BMI ≥ 30 kg/m2
27 kg/m2 ≤ BMI < 30 kg/m2 with at least one risk factor or comorbidity
Body weight change exceeding 5 kg within 3 months of the screening visit
Diabetes (Type 1, Type 2, etc.) or HbA1c ≥ 6.5% at the screening visit
Received any of the following medications or treatments within 3 months of the screening visit
Diagnosed with obesity due to endocrine disorders (hypothalamic obesity, Cushing's syndrome, insulinoma, adult growth hormone deficiency, hypothyroidism, etc.)